Philip A. Thompson, MB, MS / William G. Wierda, MD, PhD - Achieving Innovation in CLL Care With BTK Inhibitors: Selection, Safety, and Sequencing Across the Disease Continuum

1:14:16
 
Share
 

Manage episode 276913378 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/ZJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel of hematologist-oncologists offers guidance on best practices for integrating Bruton’s tyrosine kinase (BTK) inhibitor options into chronic lymphocytic leukemia (CLL) treatment by presenting real-world clinical scenarios designed to illustrate cutting-edge treatment selection and sequencing strategies across the spectrum of CLL care, from treatment-naïve to relapsed disease. Upon completion of this activity, participants should be better able to: Discuss the implications of mechanistic and selectivity differences among first- and second-generation BTK inhibitors in the context of CLL care, Summarize updated clinical evidence and practice guideline recommendations for the use of BTK inhibitors in treatment-naïve and relapsed CLL, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, or in patients unable to tolerate BTK inhibitor therapy, Develop a management plan to address unique adverse events associated with the use of BTK inhibitors in patients with CLL.

284 episodes